Chemical Engineering / Kimya Mühendisliği

Permanent URI for this collectionhttps://hdl.handle.net/11147/14

Browse

Filters

20232

Settings

Type: search.filters.itemtype.Review

Search Results

Now showing 1 - 2 of 2
  • Review
    Citation - WoS: 30
    Citation - Scopus: 33
    Molecular Separation by Using Active and Passive Microfluidic Chip Designs: a Comprehensive Review
    (Wiley, 2023) Ebrahimi, Aliakbar; Didarian, Reza; Shih, Chih-Hsin; Nasseri, Behzad; Ethan Li, Yi-Chen; Shih, Steven; İçöz, Kutay; Tarım, Ergün Alperay; Akpek, Ali; Çeçen, Berivan; Bal Öztürk, Ayça; Güleç, Kadri; Tarım, Burcu Sırma; Tekin, Hüseyin Cumhur
    Separation and identification of molecules and biomolecules such as nucleic acids, proteins, and polysaccharides from complex fluids are known to be important due to unmet needs in various applications. Generally, many different separation techniques, including chromatography, electrophoresis, and magnetophoresis, have been developed to identify the target molecules precisely. However, these techniques are expensive and time consuming. “Lab-on-a-chip” systems with low cost per device, quick analysis capabilities, and minimal sample consumption seem to be ideal candidates for separating particles, cells, blood samples, and molecules. From this perspective, different microfluidic-based techniques have been extensively developed in the past two decades to separate samples with different origins. In this review, “lab-on-a-chip” methods by passive, active, and hybrid approaches for the separation of biomolecules developed in the past decade are comprehensively discussed. Due to the wide variety in the field, it will be impossible to cover every facet of the subject. Therefore, this review paper covers passive and active methods generally used for biomolecule separation. Then, an investigation of the combined sophisticated methods is highlighted. The spotlight also will be shined on the elegance of separation successes in recent years, and the remainder of the article explores how these permit the development of novel techniques. © 2023 The Authors. Advanced Materials Interfaces published by Wiley-VCH GmbH.
  • Review
    Citation - WoS: 39
    Citation - Scopus: 37
    Engineered Liposomes in Interventional Theranostics of Solid Tumors
    (American Chemical Society, 2023) Kommineni, Nagavendra; Chaudhari, Ruchita; Conde, Joao; Cecen, Berivan; Chandra, Pranjal; Prasad, Rajendra; Tamburacı, Sedef
    Engineered liposomal nanoparticles have unique characteristicsas cargo carriers in cancer care and therapeutics. Liposomal theranosticshave shown significant progress in preclinical and clinical cancermodels in the past few years. Liposomal hybrid systems have not onlybeen approved by the FDA but have also reached the market level. Nanosizedliposomes are clinically proven systems for delivering multiple therapeuticas well as imaging agents to the target sites in (i) cancer theranosticsof solid tumors, (ii) image-guided therapeutics, and (iii) combinationtherapeutic applications. The choice of diagnostics and therapeuticscan intervene in the theranostics property of the engineered system.However, integrating imaging and therapeutics probes within lipidself-assembly liposome may compromise their overalltheranostics performance. On the other hand, liposomal systems sufferfrom their fragile nature, site-selective tumor targeting, specificbiodistribution and premature leakage of loaded cargo molecules beforereaching the target site. Various engineering approaches, viz., grafting,conjugation, encapsulations, etc., have been investigated to overcomethe aforementioned issues. It has been studied that surface-engineeredliposomes demonstrate better tumor selectivity and improved therapeuticactivity and retention in cells/or solid tumors. It should be notedthat several other parameters like reproducibility, stability, smoothcirculation, toxicity of vital organs, patient compliance, etc. mustbe addressed before using liposomal theranostics agents in solid tumorsor clinical models. Herein, we have reviewed the importance and challengesof liposomal medicines in targeted cancer theranostics with theirpreclinical and clinical progress and a translational overview.